New Guidelines for Dual Antiplatelet Therapy
Dual antiplatelet therapy (DAPT) — use of aspirin with a P2Y12 inhibitor such as clopidogrel, prasugrel, or ticagrelor — is commonly used after vascular events or procedures in patients with coronary artery disease. The duration of therapy is the subject of a new guideline from the American Heart Association and the American College of Cardiology. The guideline recommends a minimal therapy duration of 6-12 months, while therapy beyond 12 months should be reserved for patients at the highest risk of a vascular event. Low-dose aspirin generally should be continued indefinitely in all coronary artery disease patients. The full guideline was published online in the March 29 issue of Circulation.
The guideline recommends a minimal therapy duration of 6-12 months, while therapy beyond 12 months should be reserved for patients at the highest risk of a vascular event.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.